Duke logo

Emperor Reduced Ejection Fraction - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and helpful emplagliflozin (the study drug) works to treat people who have chronic heart failure with reduced ejection fraction.

What is the Condition Being Studied?

Chronic heart failure

Who Can Participate in the Study?

Adults who are:
- Diagnosed with chronic heart failure with a reduced ejection fraction  

For more information about participating in this study, please contact the study team.

Age Group
Adults

What is Involved?

If you choose to join the study, you will:
- Have multiple in-person clinic visits
- Have physical exams, blood and urine tests, and complete questionnaires about your health and how you are feeling
- Be randomized (like the flip of a coin) to receive either the study medication (emplagliflozin taken by the mouth) or a placebo (an inactive substance that is taken by the mouth)
- Be in the study for up to 38 months

Study Details

Full Title
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)
Principal Investigator
Cardiologist
Protocol Number
IRB:PRO00086449
NCT:NCT03057977
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698